Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer

Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer

Individuals who are immunocompromised (IC) due to therapy or underlying disease are at increased risk of herpes zoster (HZ). This study evaluates the public health impact of recombinant zoster vaccine (RZV) relative to no HZ vaccination for the prevention of HZ among adults aged ≥18 years diagnosed...

Full description

Bibliographic Details
Main Authors: Desmond Curran, Brandon J. Patterson, Justin Carrico, Ahmed Salem, Elizabeth M. La, Stéphane Lorenc, Katherine A. Hicks, Sara Poston, Christopher F. Carpenter
Format: Article
Language:English
Published: Taylor & Francis Group 2023-01-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
herpes zoster
herpes zoster vaccine
hematopoietic stem cell transplantation
neoplasms
breast neoplasms
hodgkin disease
public health
Online Access:http://dx.doi.org/10.1080/21645515.2023.2167907

Internet

http://dx.doi.org/10.1080/21645515.2023.2167907

Similar Items